Final efficacy and safety disclosures from the Phase I/II ARROW study of pralsetinib in advanced RET fusion–positive non–small cell lung cancer provide an endpoint-complete readout for the program. The dataset, presented with author disclosure language, reflects the culmination of ongoing translational and clinical tracking in RET-driven disease as the therapy continues in development strategy discussions.